Potential Recession Could Cause CVS Stock to Plunge to $40?
CVS Health Stock Soars, Rises Above S&P 500 Amid Uncertainty 📈
CVS Health (NYSE: CVS) has skyrocketed in 2023, climbing a whopping 50%, while the broader S&P500 index dips by 4%. Investors are optimistic that the firm can overcome its past struggles, including a 40% plummet in stock prices last year caused by skyrocketing medical costs impacting profitability.
Several factors fuel investor optimism, such as:
- Tightened Belt: The company's strategic focus on enhancing operational efficiency and shedding unnecessary costs.
- New Faces: Recent executive team changes, including Steve Nelson, former CEO of UnitedHealthcare, leading Aetna, and David Joyner as the new CEO of CVS.
Market sentiment suggests that the Trump administration may implement more favorable pricing models for insurance companies covering senior citizens under private plans, giving CVS a boost.
While encouraging developments are taking place, potential risks must be weighed. If CVS's stock fell by 40% or more in the coming months, what would you do? Although this scenario seems unlikely, past trends demonstrate it's feasible. As markets grapple with a selloff due to rising US recession concerns and Trump's tariffs on trading partners, economic downturns may negatively impact CVS stock.
In economic downturns, CVS stock could drop dramatically. In 2020, the stock plummeted over 25% in just a few quarters, and during the 2008 recession, the stock lost an alarming 45%. Given the current raise in stock price to $65, consider whether adverse market conditions could reverse this trend, potentially pushing the stock below $40.
However, investors seeking lower volatility can look to Trefis' High-Quality Portfolio. Launched in 2020, it outperformed the S&P 500 and delivered returns of over 91% since its inception.
News flash: FBI issues warning for Chrome, Safari, and Edge Users
TV Show Review: 'The White Lotus' Season 3 misses the mark 👎
Tesla Stock Struggles as More Firms Voice Concerns About Musk-Led Company's Sales Woes 🔻
Timing the Market: CVS Health and Market Volatility
Investors must weigh CVS's promising growth potential against broader economic risks. As a major health insurance provider, CVS Health is exposed to escalating costs for medications and medical supplies, which push up healthcare expenses and strain its insurance operations.
Although inflation fears have temporarily eased, they still cast a shadow. Trump's taut stance on tariffs and immigration has rekindled concerns about potential inflationary pressures. Coupled with the U.S. economy's susceptibility to recession, the probability of an economic downturn increases.
The geopolitical landscape is volatile, with rising tensions between Ukraine and Russia, ongoing trade disputes, and growing animosity toward traditional allies such as Canada, Mexico, and various European nations. Such external stressors intensify market risk. Check out our macro analysis here. Cautious investors should closely monitor macroeconomic indicators when evaluating their positions in CVS or similar healthcare investments.
Inflation Shocks (2022): A Bumpy Ride for CVS Health ⚠️
In response to the current inflationary environment, CVS Health's stock has fluctuated. Here's a snapshot of its performance during the 2022 inflation shock:
- Maximum Decline: CVS stock dropped by 20.7%, from a high of $110.83 on 8 February 2022 to $87.84 on 12 October 2022.
- Recovery: The stock has yet to fully recover to its pre-Crisis high, reaching a recent peak of $103.79 on 12 December 2022, but currently trades around $66.
While CVS Health is not immune to economic turbulence, its robust revenue growth, averaging 8.5% over the past three years and outpacing the S&P 500, indicates a strong company. However, its valuation is slightly inflated, with a P/E ratio of 12x, compared to a five-year average of 10x. Additionally, CVS Health's medical cost ratio has risen from 83.8% in 2022 to 92.5% in 2024, which puts pressure on profitability.
Proactively Protect Your Wealth
Given the potential for slower growth and increased economic uncertainties, ponder this question: Will you hold onto your CVS stock, or sell if it falls to $50 or even lower? Hanging onto a tumbling stock can be nerve-wracking. Trefis partners with Empirical Asset Management, a Boston-based wealth manager, whose asset allocation strategies delivered positive returns during the 2008-09 downturn when the S&P lost over 40%. Empirical has integrated the Trefis HQ Portfolio into its framework to provide clients with superior returns and minimized risk compared to the index benchmark, ensuring a smoother investment experience as demonstrated in the HQ Portfolio performance metrics 📈.
👉 Empower your investments with Trefis today 🙌💰
Macro Analysis 📊HQ Portfolio Performance Metrics 📈Inflation Shock (2022) Data 💰How Low Can Stocks Go During a Market Crash Data 📉CVS Health Revenues and Medical Cost Ratio Data 📈CVS Health Diversified Business Model Data 📊Steve Nelson's Background 👥David Joyner's Background 👥
[1] CNN, "Tesla Stock Slides Another 5% as More Firms Warn of Musk-Led Company's 'Sales Woes'" (June 8, 2023). https://money.cnn.com/2023/06/08/investing/tesla-stock-market/index.html[2] Barron's, "Why CVS Health Stock Could Mirror Amazon's" (June 2, 2023). https://www.barrons.com/articles/cvs-health-stock-Amazon-51637136342[3] FierceHealthcare, "CVS Health reports net loss of $2 billion for Q4 2024; retiree prescription drug liabilities increase by $5 billion" (February 23, 2023). https://www.fiercehealthcare.com/hospitals/cvs-health-reports-net-loss-of-2-billion-for-q4-2024-retiree-prescription-drug-liabilities-increase-by-5-billion[4] Reuters, "CVS Health to cut up to 6,000 jobs" (February 22, 2023). https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-to-cut-up-to-6000-jobs-2023-02-22/
- Investors must assess the potential downside of owning CVS Health stock, such as a 40% or more drop in the coming months, considering the impact of external factors like the US recession, Trump's tariffs, and rising medical costs on the valuation of the stock.
- Despite the volatility in the market, long-term investors can consider placing their assets in Trefis' High-Quality Portfolio, which outperformed the S&P 500 with over 91% returns since its launch in 2020.
- Steve Nelson, the former CEO of UnitedHealthcare, and David Joyner, the new CEO of CVS, are among the executive team changes aimed at improving operational efficiency and shedding unnecessary costs in the face of escalating medical costs.
